On Tuesday, the government agency announced Spravato nasal spray, also known as esketamine, can now be used "for the treatment of depression in adults who have tried other antidepressant ...

for SPRAVATO ® (esketamine) CIII nasal spray, making this innovative treatment the first and only monotherapy for adults living with major depressive disorder (MDD) who have had an inadequate ...

Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Esketamine nasal spray (Spravato) monotherapy was helpful in improving symptoms of treatment-resistant depression ...

Esketamine is the first monotherapy for MDD with inadequate response to two oral antidepressants, approved after a priority FDA review. Clinical trials showed esketamine's rapid efficacy, with 22. ...

The FDA approved esketamine (Spravato) nasal spray as monotherapy for adults with treatment-resistant depression who had an ...

Spravato (esketamine) is a prescription drug that’s approved to treat certain forms of depression. Esketamine comes as a nasal spray that you inhale. Specifically, Spravato is approved by the ...

Esketamine nasal spray, a rapid-acting anti-depressant, is known to be effective against TRD when administered alongside antidepressants like selective serotonin reuptake inhibitor (SSRI ...

An estimated one-third of patients with major depressive disorder have treatment-resistant depression (TRD), characterized by an inadequate response to two or more oral antidepressants (OADs).

Esketamine combined with a serotonin-norepinephrine reuptake inhibitor (SNRI) for treatment-resistant depression (TRD) was linked to significantly lower rates of several adverse outcomes than ...

"Many patients living with challenging-to-treat depression spend far too long cycling through multiple treatments that don't effectively resolve their symptoms, which can cause a significant ...